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 MASTER CHART  
DEXMEDETOMIDINE AS AN ADJUVANT TO LIGNOCAINE IN 
INTRAVENOUS REGIONAL ANESTHESIA 
ABSTRACT 
Background: In this randomized, double-blind, prospective study, the effect 
of adding dexmedetomidine as an adjuvant to lignocaine in Intravenous 
regional anesthesia is evaluated in terms of sensory and motor block onset 
time, intraoperative sedation, incidence of tourniquet pain and postoperative 
analgesia. 
Methods: After informed consent and ethical committee approval, sixty ASA 
I and II patients scheduled for the hand and forearm surgeries were included 
in this study .Patients with Raynaud disease, sickle cell anaemia or a history 
of allergy to local anesthetics and dexmedetomidine were excluded from the 
study. After the patients had been taken to operating room, blood pressure, 
peripheral oxygen saturation and heart rate were monitored. Patients divided 
into two groups, in Group A 3mg/kg 0.5% lignocaine with 0.5micrograms/kg 
dexmedetomidine and in Group B 3mg/kg 0.5% lignocaine were injected 
.Before the block,two cannula were placed, one in operative hand and other 
in the opposite hand. Operating hand is exsanguinated and using double 
tourniquet technique the drugs were injected in respective groups. 
Intraoperatively mentioned vital parameters monitored regularly at 5, 10, 15, 
20, 30, 40, 50, 60, 80, 90 and 120minutes. Sensory and motor block onset 
time, intraoperative sedation, tourniquet pain time, hemodynamics, 
postoperative analgesia and side effects were noted if present. Sedation was 
assessed using Ramsay sedation scale and postoperative analgesia assessed 
by visual analogue scale. Time since tourniquet release to VAS more than 3 
is considered total postoperative analgesia and rescue analgesia inj.diclofenac 
75mg intramuscularly given and the study is completed. 
 Results: Both the Groups were comparable in respect of age, sex, weight and 
duration of surgery. In  Group A onset of sensory block is 1.8±0.76minutes 
and motor block is 13.63±1.54 minutes, in Group B it was 5.27±0.58 minutes 
and 18.07±1.26 minutes respectively. In Group A sensory and motor 
recovery time were 18.87±3.27 minutes and 25.6±3.82 minutes and in Group 
B they were 4.8±0.7 minutes and 2.53±0.51 minutes respectively. Sedation in 
Group A was 1.77±0.43 and in Group B was 1. In Group A postoperative 
analgesia is 416.2±45.73 minutes and in Group B was 11.33±0.96 minutes. 
No side effects were noted. 
 
Conclusion: It is concluded that when Dexmedetomidine 0.5micrograms/kg 
is added to lignocaine for Intravenous regional anesthesia, it provided  
quicker onset of sensory and motor blockade, lesser  incidence of tourniquet 
pain, increased  duration of post operative analgesia and  better 
haemodynamic stability without any side effects. 
Keywords: Dexmedetomidine, tourniquet, postoperative analgesia 
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INTRODUCTION 
 Intravenous Regional Anaesthesia (IVRA) since its birth in the 
hands of August Bier in 1908 has become a valuable instrument in the 
repertoire of anaesthesiologists. This method enjoyed wide popularity for a 
time. It is not long before simple and reliable techniques for blocking the 
brachial plexus developed, and the intravenous method declined in 
popularity. 
It was revived in 1963 by Holmes, who  used lignocaine because it 
appeared to give more reliable anaesthesia than procaine. Today 
intravenous regional anesthesia with slight technical  modifications  is an 
ideal method of providing  anaesthesia for minor surgical procedures to the 
extremities performed on an ambulatory basis.  It has the advantages of 
speed of onset, rapid recovery, reliability of blockade  & cost 
effectiveness. 
 Adjuvants to local anaesthetics have greatly expanded the potential 
applications of regional anaesthesia by providing faster onset time, 
inhibition of tourniquet pain, prolonged post-operative analgesia and 
improved peri-operative analgesia apart from decreasing the risk of local 
anaesthetic toxicity. 
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 In this regard, Dexmedetomidine– a parenterally administered α2 
agonist have analgesic effects by depressing the nerve action potentials 
especially in C fibres and also acting  at α2-adrenergic receptors located at 
nerve endings . When given in combination with Local anaesthetics it 
decreases the peri-operative pain. 
 Additive effects of these agents result in greater patient satisfaction, 
rapid hospital discharge , cost effectiveness and minimal risks. 
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                                      AIM OF THE STUDY 
To assess 
1. The effectiveness of  Dexmedetomidine as an adjuvant in 
Intravenous regional anesthesia 
2. The effectiveness of Dexmedetomidine in preventing tourniquet pain 
when added as an adjuvant in Intravenous regional anesthesia 
3. The duration of postoperative analgesia, when Dexmedetomidine is 
added as an adjuvant in Intravenous regional anesthesia. 
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INTRAVENOUS  REGIONAL  ANAESTHESIA 
Intravenous regional anaesthesia (IVRA) was first described by 
August Bier in 1908. He observed that when local anaesthetic was injected 
intravenously between two tourniquets on a limb, a rapid onset of 
anaesthesia occurred in the area between the tourniquets . The technique 
did not become popular until the 1960s when it was reintroduced by 
Holmes. Today, the technique is slightly modified, using either a single or 
a double tourniquet at one site and injecting local anaesthetic as distal as 
possible to the cuff. The double tourniquet is used to increase safety and to 
reduce tourniquet pain in the awake patient, but there is a possibility of 
accidental deflation of the wrong cuff, which may lead to toxic systemic 
levels of local anaesthetic. 
Intravenous Regional Anesthesia is technically simple and does not 
require specific anatomical knowledge. Success rate is 96–100% with a 
low incidence of side-effects. It is a reliable, simple and safe method of 
providing anaesthesia for minor surgical procedures to the extremities if it 
is administered by experienced clinicians 
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Advantages and Disadvantages of intravenous regional anaesthesia 
Advantages: 
It has faster onset and rapid recovery . It is a simple and reliable 
technique providing good muscle relaxation in the absence of local 
infection and with adequate equipment.  
Disadvantages and Complications 
Postoperative analgesia is poor and provides limited time of surgical 
anaesthesia for less than 90 minutes. There is  potential for systemic local 
anaesthetic toxicity. Nerve damage can occur secondary to direct 
compression by the  tourniquet and very rarely compartment syndrome 
and loss of limb can occur as complications. 
Mechanism of action:  
Local anaesthetic diffuses into the small veins surrounding the 
nerves and then into the vasa nervorum and capillary plexus of the nerves, 
leading to a core to mantle (centrifugal) conduction block in the nerves 
involved. Local anaesthetic then diffuses into the small nerves in the skin, 
blocking their conduction. The tourniquet produces ischaemia, which 
contributes to the analgesic action of the local anaesthetic by blocking 
nerve conduction and motor end plate function.  Tourniquet application for 
20 minutes alone produce analgesia to pinprick without the injection of 
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any local anaesthetic. However, the speed of onset and the density of 
anaesthesia are greater with injection of local anaesthetic. 
Indications: 
Intravenous Regional Anesthesia  is used for surgical interventions 
on the hand, forearm or elbow that will not exceed 1 hour. These include 
reduction of forearm fractures, excision of wrist ganglia and palmar 
fasciotomy. Intravenous Regional Anesthesia is particularly useful for 
tendon grafting because it enables the surgeon to observe movement and 
tension of the grafted tendon  after deflating the tourniquet before closing 
the wound , anaesthesia continued with a wrist block. Intravenous 
Regional Anesthesia  can also be used for surgery on the foot, ankle or 
lower leg, for example for removing plates, screws or foreign bodies. 
Surgery on the elbow or knee is poorly tolerated using Intravenous 
Regional Anesthesia.   
Contraindications  
Absolute contraindications include sickle cell disease, Raynaud’s 
disease or scleroderma, allergy to local anaesthetics and patient refusal. 
Relative contraindications include severe hypertensive or peripheral 
vascular disease, local infection, and skeletal muscle disorders or Paget’s 
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disease where the local anaesthetic may spread to the systemic circulation 
through the venous channels in bone. 
Procedure 
Before the procedure the patient should be starved for 6 hours and 
monitored closely using standard monitoring . Patient should be  placed on 
a tipping trolley and adequately informed about the procedure and have 
consented to it. 
The equipment required for Intravenous regional anesthesia includes 
pneumatic tourniquet which is checked for leaks before the procedure, a 
pressure gauge, Esmarch bandage or Rhys-Davis exsanguinator, local 
anaesthetic solution, resuscitation equipment and drugs. 
INTRAVENOUS REGIONAL ANESTHESIA OF THE ARM:  
A 22 G cannula is placed intravenously as distal as possible in the 
arm to be anaesthetized. Venous access is established in the opposite arm 
to allow administration of fluids or drugs if necessary. In the double 
tourniquet technique ,two tourniquets each 6 cm wide is applied on the 
arm with generous layers of padding, ensuring that no wrinkles are formed 
and the tourniquet edges do not touch the skin. The arm is exsanguinated 
either by using the Esmarch bandage or a Rhys-Davis exsanguinator. If 
this is impossible, exsanguination can be achieved by elevating the arm for 
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2–3 minutes while compressing the axillary artery. The distal tourniquet is 
inflated to atleast  100 mmHg  higher than the patient’s systolic blood 
pressure or the tourniquet is inflated until the radial pulse was not felt . 
The proximal tourniquet is inflated to the same pressure. After ensuring 
inflation, the distal cuff is deflated. 
Before injecting local anaesthetic it must be confirmed that no radial 
pulse is palpable. The local anaesthetic is then injected slowly. A standard 
volume for injection into the upper limb is 40 ml, which can be increased 
to 50 ml in a fit, large adult. If the injection is too rapid, the venous 
pressure may exceed the tourniquet pressure and the local anaesthetic 
solution may escape into the systemic circulation. Surgical anaesthesia is 
usually achieved within 15 minutes. The distal tourniquet, which overlies 
part of the anaesthetized arm, can then be inflated and the proximal one 
deflated to relieve tourniquet pain. 
The cuff should not be deflated until 20 minutes after local 
anaesthetic injection because systemic toxic doses of local anaesthetic may 
occur. After 20 minutes, 30% of the injected drug is fixed within the 
tissues and is unavailable for immediate release into the systemic 
circulation. Cuff deflation should be performed in cycles with 
deflation/inflation times of less than 10 seconds until the patient no longer 
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exhibits signs of systemic toxicity for example, tingling of the lips, tinnitus 
and drowsiness. Severe signs of systemic toxicity include bradycardia, 
hypotension, electrocardiogram abnormalities, seizures and loss of 
consciousness. Maximum blood levels of local anaesthesia occur within 10 
minutes of cuff deflation. Therefore, the patient should be monitored 
closely for 30 minutes following tourniquet release. With lignocaine, 2.5–
3 mg/kg, and cuff deflation after 10 minutes, blood levels have been 
reported to be less than 2 micrograms/ml. 
If severe central nervous system intoxication occurs, appropriate 
resuscitation guidelines should be followed. Emergency drugs must be 
readily available and 100% oxygen should be administered. 
INTRAVENOUS REGIONAL ANESTHESIA OF THE LEG:  
The basic technique is the same as for the arm but the dose and 
volume of local anaesthetic has to be doubled for intravenous regional 
anesthesia of the leg, which is associated with an increased potential for 
local anaesthetic toxicity. The tourniquet pressure must be higher in the 
leg  approximately 350–400 mmHg, to occlude blood flow in the femoral 
artery. This may increase the occurrence of tourniquet pain. Tourniquets 
may be applied to the thigh, two tourniquets about 9 cm wide  or one at the 
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calf  below the head of the fibula  and one at the thigh. The latter is for 
safety in case of distal cuff failure and is not usually inflated. 
Choice of drugs 
Many local anaesthetic drugs, with or without additives, have been 
used for intravenous regional anesthesia, but 0.5% prilocaine, 3–6 mg/kg, 
is the drug of choice because it has less systemic toxicity and is partially 
taken up in the lungs before reaching the systemic circulation. The usual 
dose is 40 ml (200 mg) without epinephrine. However, the manufacturers 
have ceased production of 0.5% prilocaine. 1% prilocaine remains 
available and is licensed for intravenous regional anesthesia, though its 
stability is not guaranteed if diluted.  If prilocaine is unavailable then 0.5% 
lignocaine, 3 mg/kg, is used. If intravenous regional anesthesia is applied 
to the leg a larger volume must be injected (up to 100 ml). Prilocaine can 
be used undiluted  for which maximum recommended dose is 400 mg in 
adults but lignocaine is commonly diluted to lower concentrations (e.g. 
0.2–0.25%).For a 60kg patient 9ml of 2% lignocaine diluted to 36ml is 
0.5% is used for Intravenous regional anesthesia. 
Prilocaine can cause methaemoglobinaemia but unless doses in 
excess of 600 mg are used it is clinically insignificant in most patients. 
Although one has to be aware that in patients with anaemia or cardiac 
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conditions even small amounts of methaemoglobin can significantly 
impair the oxygen-carrying capacity of their red blood cells. Intravenous 
regional anaesthesia with prilocaine in these patients should be considered 
carefully for its benefits. 
Other local anaesthetic agents have been used but do not provide 
superior analgesia or more rapid onset of block. Severe toxic reactions and 
death have been observed with bupivacaine and its use is contraindicated. 
In one study, 0.2% ropivacaine was intraoperatively as effective as 0.5% 
prilocaine but postoperative analgesia was prolonged;  
Additives to local anaesthetics have not been consistently shown to 
have an effect during  intravenous regional anesthesia  but may increase 
the length of postoperative analgesia, probably because of a systemic 
effect following tourniquet release. The reported enhancement of 
intravenous regional anesthesia with pethidine, 1 mg/kg, may reflect 
intrinsic local anaesthetic activity of the drug. 
It was shown that addition of muscle relaxants produced marked 
muscle relaxation but did not augment analgesia. 
          Ketamine alone appears to provide good sensory analgesia but some 
patients lost consciousness and exhibited the typical features of ketamine 
anaesthesia after tourniquet release. 
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Many other drugs have been studied, but only the addition of α2 
agonists clonidine 150micrograms or Dexmedetomidine 0.5     
micrograms/kg   or the non-steroidal anti-inflammatory drugs ketorolac, 
20 mg, or tenoxicam, 20 mg, to the local anaesthetic solution appeared to 
be effective in prolonging postoperative analgesia and relieving tourniquet 
pain. Guanethidine and calcium-channel blockers have been evaluated in 
the context of chronic pain management only. 
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TOURNIQUET 
Intravenous regional anaesthesia is a method of producing analgesia 
of the distal part of a limb by intravenous injection, while circulation to the 
limb is occluded. 
 Occlusion of the limb was done previously by winding an esmarch 
bandage proximally up the arm. At present occlusion of the limb is 
achieved by pneumatic tourniquet. Unfortunately, the tourniquet is not 
physiologic and is associated with number of disadvantages. 
SITE OF APPLICAION: 
 The upper arm and thigh have sufficient muscle bulk to distribute the 
cuff pressure evenly and they are the recommended sites. 
CUFF WIDTH: 
 The American Heart Association concluded that if a 
sphygmomanometer cuff has a width of 20% greater than the diameter of 
the upper arm or 40% of the circumference of the thigh  to a maximum of 
20cm , then the pressure in the underlying central artery will be equal to 
that in the cuff.  Modern silicone cuffs tend to be smaller than this, 
measuring 90mm cuff width of  bladder 70mm size  for the arm and 
105mm cuff width of  bladder 75mm size for the leg. 
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 The tissues immediately underlying the cuff should be protected 
with cotton wool. This is not necessary with correctly applied modern 
silicone cuff 
PRESSURE: 
 It is based on the unsedated patient’s blood pressure measured on the 
ward preoperatively. The recommended cuff pressure for the upper limb is 
systolic blood pressure plus 100mmHg and for lower limb twice systolic 
blood pressure. This higher pressure is needed because there is often not 
enough room above the operating site for full sized cuff. 
TOURNIQUET TIME: 
 The recommended time for upper limb is 90minutes. Two hours 
should be regarded as a maximum but this will not be safe for all patients. 
The surgeon should be notified about tourniquet time every half an hour. 
The safest time is the shortest tourniquet time. 
PHYSIOLOGIC CHANGES CAUSED BY LIMB TOURNIQUETS: 
            Neurologic effects are abolition of somatosensory evoked 
potentials and nerve conduction which occurs with in 30minutes , 
application for more than 60minutes causes tourniquet pain and  
hypertension ,  application for more than 2hours may result in 
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postoperative neuropraxia and evidence of nerve injury may occur at a 
skin level underlying the edge of the tourniquet 
MUSCLE CHANGES: 
  It produces cellular hypoxia  with in 8minutes , decrease in the  
cellular creatine level , progressive cellular acidosis , endothelial capillary 
leak  after 2hours and  progressive coldness of limb. 
SYSTEMIC EFFECTS OF TOURNIQUET INFLATION: 
Arterial and pulmonary artery pressures become elevated, although 
this effect is usually slight to moderate if only one limb is occluded 
SYSTEMIC EFFECTS OF TOURNIQUET RELEASE: 
 They are transient fall in core temperature, transient metabolic 
acidosis , transient fall in central venous oxygen tension ,transient increase 
in central venous carbondioxide tension , rapid release of acid metabolites 
into central circulation , transient fall in pulmonary and systemic arterial 
pressures, transient increase in end – tidal carbondioxide and increased 
oxygen consumption. 
TOURNIQUET PAIN: 
 Patients receiving spinal anaesthesia may develop a poorly defined 
aching or burning sensation in the distal extremity about one hour after 
tourniquet inflation. Although the mechanism and neural pathways for this 
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severe aching and burning sensation defy precise explanation, 
unmyelinated, slow –conduction C fibres, which are relatively resistant to 
local anaesthetic blockade, probably play a critical role. Even during 
general anaesthesia, tourniquet pain can be revealed by a gradually 
increasing mean arterial blood pressure. The tourniquet pain and its 
accompanying hypertension influenced by many factors including 
anaesthetic techniques, intensity and level of block, choice of local 
anaesthetic  and supplementation of the block with opioids. Cuff deflation 
invariably and immediately relieves the sensation of tourniquet pain and 
its hypertension. Systemic opioids namely inj.fentanyl 1micrograms/kg 
can be used in relieving tourniquet pain. 
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PHARMACOLOGY  OF LIGNOCAINE 
Lignocaine is a synthetic amide-linked anaesthetic of intermediate 
potency and duration.  In 1943 Lofgren synthesized Lignocaine in 
Sweden. First used by Gordh in 1948. 
Lignocaine is the standard to which all other local anaesthetics are 
compared.  It is currently the most widely used local anaesthetic.  In 
addition, it is a popular antiarrythmic.  It can be given by all routes. 
Mechanism of action: 
 Lignocaine prevent transmission of nerve impulses by inhibiting 
passage of sodium ions through ion-selective sodium channels in the nerve 
membranes.  This slows the rate of depolarization such that the threshold 
potential is not reached and thus action potential is not propagated.  But 
resting membrane potential is not altered.  Lignocaine binds to the inner 
portion receptor (i.e Sodium channel) after entering the cell membrane. 
Physiochemical properties: 
Molecular weight   234 
Weak base with a pka  7.6 – 7.8 
Very stable, not decomposed by boiling, acids or alkalies 
It is less lipid soluble than that of Bupivacaine 
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Pharmacokinetics: 
Absorption: 
 It is absorbed from the site of application or injection into the blood 
stream.  Rate of absorption depends on the blood flow to the area and use 
of epinephrine. 
Metabolism and Excretion: 
 Metabolised in liver by oxidative dealkylation to monoethylglycine 
xylidide followed by hydrolysis of this metabolite to xylidide.  Metabolism 
is dependant on hepatic blood flow. Monoethylglycine xylidide has 80% 
activity of the parent drug and  xylidide has 10% activity of the parent 
drug. 75% of xylidide is excreted in the urine as 4 – hydroxyl – 2,6 –
dimethylaniline. 
Onset of action: 
 It has rapid onset occurring for topical anaesthesia in 5-10 minutes, 
for conduction anaesthesia in small nerves  it is 5-10 minutes and for large 
nerves it is 10-15 minutes and for Intravenous administration it is 1-2 
minutes.  
            It has protein binding of 70% bounded to α1 acid glycoproteins 
with volume of distribution 91 litres. Lignocaine has a triphasic 
distribution 
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Rapid distribution phase (α): In this phase, the drug is distributed to highly 
vascular regions with t ½ α of  1 minute. Next is slow disappearance phase 
(β): here the drug is distributed to slowly equilibrating tissues with t ½ β of 
9.6 min.Last is slow transformation and excretion phase ( δ ) : Where the 
t½ δ is 1.6 hrs with clearance of 0.95 litres per minute. 
Availability: 
a) 5% heavy 2 ml ampoules which contain 50 mg of lignocaine / ml 
with 75 mg – 100 mg of dextrose 
b) 2% ligcocaine (xylocard) without preservative – 50 ml vial for 
intravenous use 
c) 2% lignocaine – plain – 30 ml vial –contains methyl and propyl 
paraben as preservative 
d) 2% lignocaine with 1 in 200000 Adrenaline 
e) 4% lignocaine with 1 in 200000 Adrenaline – 30 ml vial. 
f) 4% lignocaine viscus 
g) 4% lignocaine aqueous solution 
h) 10% lignocaine spray 
i) 2% lignocaine Jelly 
j) 2% lignocaine ointment  
k) 5% lignocaine ointment 
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Pharmacodynamics: 
Local actions: 
 Causes nerve blockade with loss of pain and temperature sensation, 
touch, motor power and vasomotor tone in the region supplied by the 
nerves blocked. 
Systemic actions: 
 The results of systemic absorption from the site of administration or 
intravenous administration 
1. Cardiovascular system: 
It has a stabilizing effect on the cell membranes of cardiac tissue. 
Lignocaine depresses myocardial automaticity by antagonizing the 
spontaneous phase IV depolarization and reduces the duration of effective 
refractory period. Myocardial contractility and conduction velocity are 
depressed at higher concentrations.  These effects result from direct cardiac 
muscle membrane changes occurring due to cardiac sodium channel 
blockade. It stabilizes the membrane of damaged and excitable cells, 
tending to suppress ectopic foci.  
2. Vascular smooth muscle : 
 Produces vasodilatation 
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3. Respiratory system : 
 Lignocaine depresses hypoxic drive (the ventilatory response to low 
PaO2).Apnea can result from phrenic and intercostal nerve paralysis or 
depression of the medullary respiratory center following direct exposure to 
the local anaesthetic agents.Relaxes bronchial smooth muscle.Intravenous 
lignocaine may be effective in blocking the reflex bronchoconstriction 
associated with intubation. 
4. Central nervous system : 
 Produces a sequence of stimulation followed by depression. 
Produces sedation on intravenous administration.Intravenous 
administration decreases cerebral blood flow and attenuates the rise in 
intracranial pressure that accompanies intubation.Infusion of lignocaine is 
capable of reducing the Minimal Alveolar Concentration of volatile 
anaesthetics by 40%. 
5. Musculoskeletal: 
Lignocaine is myotoxic leading to lytic degeneration, edema and 
necrosis. 
6. Haematological : 
It decreases coagulation and enhances fibrinolysis 
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Indications: 
1. For infiltration block, peripheral nerve blocks, epidural, spinal and 
topical anaesthesia & intravenous regional anaesthesia. 
2. Antiarrythmic: 
Lignocaine is a class IB antiarrythmic.It is used to treat 
a) Ventricular tachyarrythmias 
b) Arrythmias following acute Mycardial Infarction during cardiac 
surgery 
c) In digitalis toxicity – because it does not worsen AtrioVentricular 
– block 
3. Prevention or treatment of increases in intracranial pressure during 
intubation - antitussive effect may be the reason. 
4. Reflex induced bronchospasm is also attenuated by intravenous 
administration of lignocaine 
5. Suppresses noxious reflexes such as coughing & sympathetic 
stimulations associated with endotracheal suctioning and intubation. 
6. Used intravenously as an analgesic for certain chronic pain states 
7. Used as a supplement to general anaetheisa. 
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Contraindications: 
1. Hypersensitivity 
2. Should not be used with vasoconstrictor in digits of hand, feet and penis 
3. Stokes Adams syndrome, severe degree of heart block 
Doses: 
Maximum recommended dose : 
a) Plain    - 3 mg / kg 
b) with adrenaline  - 7 mg / kg 
c) for reflex suppression  -   1.5 mg / kg  iv. 
Drug interactions: 
β  Blockers: 
 Coadministration of beta blockers, increases serum levels of 
lignocaine and its toxicity by decreasing lignocaine’s metabolism. 
Anticonvulsant agents: 
 Increases lignocaine’s metabolism 
Non depolarizing muscle relaxant 
 Blockade is potentiated by lignocaine 
Opioids and  α 2 adrenergic agonists : 
 Potentiate lignocaine’s pain relief 
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Antiarrythmic agents 
 Potentiate the cardiac effects of lignocaine 
Toxicity: 
Mostly due to systemic absorption of locally administered lignocaine 
or due to accidental intravenous administration of large doses of 
lignocaine. The central nervous system is mostly vulnerable. 
Blood levels and symptoms: 
4 micrograms / ml  :  Light headedness, tinnitus, circumoral and 
tongue numbness  
  (anticonvulsant and antiarrhythmic activity) 
6 micrograms / ml  :   visual disturbances 
8 micrograms / ml   :  muscular twitching 
10 micrograms  / ml :   convulsions 
12 micrograms  / ml   :   Unconsciousness 
15 micrograms  / ml   :   Coma 
20 micrograms  / ml  :   respiratory arrest 
26 micrograms  / ml    :  cardiovascular collapse 
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Treatment of toxicity: 
 Continuous monitoring of Cardiovascular and Respiratory status 
helps to identify the toxicity earlier. 
• If convulsions occur barbiturates or benzodiazepines can be given. 
• Succinylcholine 1mg/kg to paralyse the patient and aids in 
controlling the seizures. 
• Cardiac toxicity like fibrillation can be treated by defibrillation 
• Ventilatory support – 100 % oxygenation, intubation and ventilation 
• Maintain B.P. by rapid infusion of I.V. fluids, use of vasopressors 
and put the patient in Trendelenberg’s position. 
• Maintain fluid and electrolyte balance. 
Adverse effects: 
1. Allergic and hypersensitivity reactions 
 Due to the preservative used – methyparaben 
2. Cardiovascular system : 
 Bradycardia, hypotension 
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PHARMACOLOGY OF DEXMEDETOMIDINE 
      Dexmedetomidine hydrochloride is a 4-((s)-alpha,2,3-trimethylbenzyl) 
imidazole monohydrochloride or 4-[(1r)-1-(2,3-dimethylphenyl) ethyl]-3h-
imidazole hydrochloride. 
Molecular weight  236.74 1043  
Dexmedetomidine is a new alpha2-agonist used as a short-term (less 
than 24 h) sedative analgesic in the intensive care unit. Clonidine is the 
prototype of alpha2- agonist. Dexmedetomidine when compared to 
clonidine is a much more selective  alpha 2-adrenoceptor agonist, the 
alpha2/alpha1 selectivity of dexmedetomidine is 1620 and hence is 8 times 
more powerful alpha2-adrenoceptor than clonidine . In addition, 
dexmedetomidine is shorter-acting drug than clonidine and has a reversal 
drug for its sedative effect, atipamezole. These properties render 
dexmedetomidine suitable for sedation and analgesia during the whole 
perioperative period: as premedication, as an anesthetic adjunct for general 
and regional anesthesia, and as postoperative sedative and analgesic. 
Alpha2-receptors are found in many sites throughout the body. 
Alpha2-adrenoceptors are found in peripheral and central nervous systems, 
in effector organs such as the liver, kidney, pancreas, eye ,vascular smooth 
muscles and platelets . Alpha2-adrenoceptors are divided into three 
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subthypes;  the subtype a, the predominant subtype in central nervous 
system, is responsible for the sedative, analgesic and sympatholytic effect; 
the subtype b, found mainly in the peripheral vasculature, is responsible 
for the short-term hypertensive response, and the subtype c, found in the 
central nervous system , is responsible for the anxiolytic effect. 
Pharmacodynamics of dexmedetomidine 
  The highest densities of alpha2- receptors are found in the locus 
ceruleus, the predominant noradrenergic nuclei of the brainstem and an 
important modulator of vigilance. Presynaptic activation of the alpha2-a 
adrenoceptor in the locus ceruleus inhibits the release of norepinephrine  
and results in the sedative and hypnotic effects  in addition, the locus 
ceruleus is the site 
of origin for the descending medullospinal noradrenergic pathway, known 
to be an important modulator of nociceptive neurotransmission. 
                         Stimulation of the alpha2-adrenoceptors in this area 
terminates the propagation of pain signals leading to analgesia. 
Postsynaptic activation of alpha2-adrenoceptors in the CNS results in 
decrease in sympathetic activity  leading to hypotension and bradycardia. 
At the spinal cord, stimulation of alpha2-receptors at the substantia 
gelatinosa of the dorsal horn leads to inhibition of the firing of nociceptive 
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neurons and inhibition of the release of substance p10. Also, the alpha2-
adrenoceptors located at the nerve endings have a possible role in the 
analgesic mechanisms of alpha2-agonists by preventing noradrenaline 
release. 
Pharmacokinetics of dexmedetomidine 
Dexmedetomidine, an imidazole compound, is the active d-isomer of 
medetomidine. Following intravenous administration, dexmedetomidine 
exhibits the following pharmacokinetic parameters: a rapid distribution 
phase with    distribution half-life (t ½ α) of 6 minutes ; elimination half-
life (t ½ β) of 2 hours;  volume of distribution (vss) 118 litres. 
Dexmedetomidine exhibits linear kinetics when infused in the dose range 
of 0.2-0.7 micrograms/kg/h for not  more than 24 hours. Dexmedetomidine 
undergoes almost complete biotransformation through direct 
glucuronidation and cytochrome p450 metabolism. Metabolites of 
biotransformation are excreted in the urine (95%) and feces. The average 
protein binding of dexmedetomidine is 94%. Dexmedetomidine is a white 
powder that is freely soluble in water and  pka of 7.1 
Dosage 
It is supplied as 100 micrograms/ml 2 ml vial which must be diluted 
with 48 ml of 0.9% sodium chloride solution  prior to administration. For 
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adult patient, dexmedetomidine is administered by a loading infusion of 
0.5-1 micrograms/kg over 10 minutes, followed by a maintenance infusion 
of 0.2 to 0.7 micrograms/kg/hr. The effect appears in 5-10 minutes, and is 
reduced in 30-60 minutes. The maintenance infusion is adjusted to achieve 
the desired level of sedation. 
Perioperative uses of dexmedetomidine 
i – Premedication 
              Dexmedetomidine  possesses anxiolytic, sedative, analgesic, 
antisialogogue and sympatholytic properties.  Intramuscular 
dexmedetomidine  at a dose of 1 microgram/kg is  used for premedication . 
ii – Intraoperative uses of dexmedetomidine 
Intraoperative uses of dexmedetomidine include its use as adjunct to 
general anesthesia, as adjunct to regional anesthesia, in monitored 
anesthesia care (MAC), or as a sole agent for total intravenous anesthesia 
(TIVA). 
iii – Use of dexmedetomidine in the postoperative period 
     Dexmedetomidine’s  special properties favor its use in the recovery 
room. In addition to its sympatholytic effects, analgesic effects , decreased 
rate of shivering and the preservation of respiratory function allows the 
continuation of the dexmedetomidine infusion in the extubated, 
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spontaneously breathing patient. The possibility of ongoing sedation and 
sympathetic block could be beneficial in reducing high rates of early 
postoperative ischemic events in high-risk patients undergoing non-cardiac 
surgery. 
Contraindication 
i) Pre-existent severe bradycardia and conduction problems.  
ii)  In patients with reduced ventricular functions (ejection 
fraction<30%) 
iii) In patients who are hypovolemic or hypotensive. 
Adverse effects  
           The common adverse effects of dexmedetomidine  include 
hypotension, hypertension, nausea, bradycardia, atrial fibrillation, hypoxia  
and various atrioventricular blocks.  
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                        REVIEW OF LITERATURE  
1. Addition of dexmedetomidine to lidocaine for intravenous regional 
anaesthesia. Esmaoglu, A.; Mizrak, A.; Akin, A.; Turk, Y.; Boyaci, A. 
Erciyes University Medical Faculty, Department of Anaesthesiology 
and Reanimation, Kayseri, Turkey. 
              Esmaoglu et al  tested the use of adjuncts for intravenous 
regional anaesthesia (IVRA) for surgical procedures in terms of their 
intraoperative effects and postoperative analgesia in forty patients 
undergoing hand surgeries.They concluded that addition of 1 
micrograms kg-1 dexmedetomidine to lidocaine  in intravenous regional 
anaesthesia  improved the quality of anaesthesia and decreased 
analgesic requirements, but had no effect on the sensory and motor 
blocks onset and regression times. 
2. Adding dexmedetomidine to lidocaine for intravenous regional 
anesthesia. Memis D, Turan A, Karamanlioglu B, Pamukcu Z, Kurt I. 
department of anesthesiology and biostatistics, Trakya university 
medical faculty,edime,Turkey 
        A recent study by Memis et al  found that the addition of 
dexmedetomidine 0.5 micrograms kg-1 to lidocaine for Intravenous 
regional anaesthesia leads to significant decreases in sensory and motor 
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blocks onset time ,improves quality of anesthesia , postoperative 
analgesia without any side effects. 
3. Dexmedetomidine: Clinical Application as an Adjunct for Intravenous 
Regional Anesthesia. Usha Ramadhyani, MD,Jason L. Park, 
MD,Dominic S. Carollo, MS, MD,Ruth S. Waterman, MD, Bobby 
D. Nossaman, MD 
          Intravenous regional anesthesia is limited by the development 
of tourniquet pain and its inability to provide postoperative analgesia. 
In this study it was found  that  adding  dexmeditomedine as an  
adjuvant  in intravenous regional anaesthesia  improved  block quality, 
prolong post deflation analgesia and decreased  tourniquet pain. 
4. Adding clonidine to lidocaine for intravenous regional anesthesia 
prevents tourniquet pain.Gentili M, Bernard JM, Bonnet F. 
             Gentili et al were the first to report the efficacy of clonidine in 
intravenous regional anaesthesia  in decreasing tourniquet pain. Reuben 
and Sklar  evaluated the safety and efficacy of administering 
intravenous regional anaesthesia  with 1 micrograms/kg clonidine in the 
management of complex regional pain syndrome of the knee and found 
that clonidine was a useful treatment modality for its management 
without significant side effects. 
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5. Clonidine versus ketamine to prevent tourniquet pain during 
intravenous regional anesthesia with lidocaine .Gorgias NK, Maidatsi 
PG, Kyriakidis AM,  
     They compared the efficacy of a 1 micrograms/kg clonidine 
added to intravenous regional anaesthesia with lidocaine to prevent 
tourniquet pain and found that the addition of 1 micrograms/kg 
clonidine to lidocaine for intravenous regional anaesthesia  delayed the 
onset of unbearable tourniquet pain and decreased analgesic 
consumption for tourniquet pain relief. 
6.  Lurie et al. evaluated the efficacy of 1 micrgramsg/kg clonidine added 
to intravenous regional anaesthesia -lidocaine in decreasing the onset of 
severe tourniquet pain and found that it delayed the onset time 
7. Fentanyl and  Dexmedetomidine premedication before intravenous 
regional anesthesia in minor outpatient hand surgery.  
        Jaakola et al. demonstrated the analgesic efficacy of 
dexmedetomidine in human tourniquet pain. In their study, a single 
intravenous  dose of fentanyl and dexmedetomidine (0.25, 0.5, and 1 
micrograms/kg) was administered. They found that dexmedetomidine 
clearly demonstrated an analgesic effect in the tourniquet pain .  
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8. Jaakola assessed the efficacy and safety of  intravenous 
dexmedetomidine as a premedication before intravenous regional 
anaesthesia . She found that 1 micrograms/kg dexmedetomidine was an 
effective premedication before intravenous regional anaesthesia  
because it reduced patient anxiety and sympathoadrenal responses. 
9. Addition of dexmedetomidine or lornoxicam to prilocaine in intravenous 
regional anaesthesia for hand or forearm surgery .Kol IO, Ozturk H, 
Kaygusuz K, Gursoy S, Comert B, Mimaroglu C. Department of 
Anaesthesiology, Cumhuriyet University School of Medicine, Sivas, 
Turkey. 
     Addition of dexmedetomidine or lornoxicam to prilocaine in  
intravenous regional anaesthesia decreased Visual Analogue pain 
scores, improved anaesthesia quality and decreased analgesic 
requirement. 
10. A systematic review of adjuncts for intravenous regional anaesthesia 
for surgical procedures.  Andrew Choyce  MBCHB FRCA and Philip 
Peng, MBBS FRCPC. From the Department of Anaesthesia, King’s 
college Hospital, Denmark Hill, London, UK and the Toronto Western 
Hospital, Canada. 
35 
 
   The authors tested the use of adjuncts for intravenous regional 
anaesthesia (IVRA) for surgical procedures in terms of their 
intraoperative effects and postoperative analgesia. 
   They concluded that, there is good evidence to recommend 
Non-steroidal anti-inflammatory drugs  in general and ketorolac in 
particular for improving post operative analgesia after intravenous 
regional anaesthesia.  Clonidine also appears to improve post operative 
analgesia and prolong tourniquet tolerance.  Opioids are disappointing 
by this route.  Only 30 mg meperidine has substantial postoperative 
benefit but at the expense of post deflation side effects.  Muscle 
relaxants improve motor block and aid fracture reduction. 
11. An evaluation of the analgesic efficacy of intravenous regional 
anaesthesia with lidocaine and ketorolac using a forearm versus upper 
arm tourniquet.  Scott s. Reuben, MD., Robert B. Steinberg, MD, PhD, 
Holly Maciolek, RN and Poornachandran Manikantan MD, Department 
of Anaesthesiology, Tuffs University School of Medicine, 
Massachusetts. 
   In this study, they assessed the analgesic efficacy of 
administering intravenous regional anaesthesia by administrating 
lidocaine and ketorolac with either a forearm or upper arm tourniquet 
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for outpatient hand surgery.  They concluded that forearm tourniquet 
intravenous regional anaesthesia with 0.5% lidocaine and ketorolac 
provides  both a longer duration of sensory block and prolonged 
postoperative analgesia compared with upper arm intravenous regional 
anaesthesia. 
12. Local anaesthetic adjuvants for neuraxial and peripheral  blockade – 
James R. Hebl, MD, Department of Anaesthesiology Mayo – clinic, 
USA.  
In this study, they studied about various local anaesthetic additives 
such as opioids, alpha – 2 agonists (clonidine), acetylcholine esterase 
inhibitors(neostigmine) and N methyl – D aspartate receptor antagonists 
(Ketamine) and Non-steroidal anti-inflammatory drugs . 
They demonstrated that more effective postoperative analgesia can 
be achieved when Ketorolac is used in conjunction with lidocaine for 
intravenous regional anaesthesia .  They hypothesized that more effective 
analgesia was obtained during intravenous regional anaesthesia 
administration because a higher concentration of ketorolac existed at the 
site of surgical trauma, where inflammatory mediator synthesis occured. 
13.Comparision of wound infiltration with ketorolac  Versus intravenous 
regional anaesthesia with ketorolac for postoperative analgesia 
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following ambulatory hand surgery.- Reuben SG, Duprat MM, Tufts 
University school of Medicine, spring field, Massachusetts, USA. 
 The purpose of this study was to assess the analgesic effectiveness of 
ketorolac administered with lidocaine via intravenous regional 
anaesthesia (IVRA) or via wound infiltration following ambulatory 
hand surgery.  They concluded that ketorolac provides similar 
postoperative analgesia after ambulatory hand surgery when 
administered with lidocaine either by intravenous regional anaesthesia 
or by wound infiltration. 
14. Intravenous Regional Anaesthesia using prilocaine and neostigmine.  
A. Turan, B. Karamanlyog M, D. Memis, G. Kaya and Z. Paukcy ; 
Department of Anaesthesiology and Reanimation, Trakya University, 
Turkey. 
   In this study, thirty patients undergoing hand surgery were 
randomly assigned to two groups to receive intravenous regional 
anaesthesia.  They have used 0.5 mg of neostigmine as a additive.  They 
found shortened sensory and motor block onset times, improved quality 
of anaesthesia and prolonged sensory and motor block recovery times, 
and prolonged time to first analgesic requirement in neostigmine group. 
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15. 0.5 % versus 1.0%  2 – chloroprocaine for Intravenous Regional 
Anaesthesia : A prospective randomized, Double – Blind Trial. 
 Stephan C. Marsch, MD, D Phil, Mathias Sluga, MD, Wolfgang studer, 
MD, Jonas Barandun, MD, Domenic Scharplatz, MD and wolf gang 
Ummentioter MD, From the Departments of Anaesthesia and surgery, 
Switzerland. 
   In this randomised prospective double – blind study they 
tested the hypothesis that compared with 40 ml chloroprocaine 0.5 %, 
40 ml chloroprocaine 1 % results in an earlier onset of analgesia 
duration and improves distal tourniquet tolerance during intravenous 
regional anaesthesia.  These beneficial effects must be weighed against 
a fourfold increase in signs of systemic local anaesthetic toxicity. 
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                          MATERIALS AND METHODS 
 This is a prospective randomized double blind control study 
conducted at Government Rajaji Hospital attached to Madurai Medical 
College. 
 After obtaining approval from  the ethical committee 60 patients of 
ASA grade I & II  age between 20-60 years who came for upper limb 
surgeries  lasting for less than 90 minutes were included in this study. 
 Patients with history of allergy to local anaesthetics, sickle cell 
disease, raynaud’s disease, scleroderma, local infection, Pagets disease and 
patients with inadequate starvation  less than 6 hours and patients who had 
contraindication to Dexmedetomidine were excluded from this study.  
Preanaesthetic evaluation was done.  
 All patients were premedicated with Inj. Midazolam 0.15mg/kg  
intramuscularly  45 minutes before surgery.  Resuscitation equipment and 
drugs were kept ready. The initial pulse rate, blood pressure and arterial 
oxygen saturation were recorded and then continous monitoring was done 
during the procedure.  
 A 22 G cannula was placed intravenously as distal as possible in the 
arm to be anaesthetized.  Venous access was established in the opposite 
arm to allow administration of fluids or drugs if necessary.  The double 
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tourniquet was applied on the arm with generous layers of padding, 
ensuring that no wrinkles are formed and the tourniquet edges do not touch 
the skin.  The arm was exsanguinated by using Esmarch bandage.  If this 
was impossible, exsanguination was achieved by elevating the arm for 2-3 
minutes while compressing the axillary artery. 
 The proximal tourniquet was inflated to at least 100 mm Hg higher 
than the patients systolic blood pressure.  Before injecting local 
anaesthetic, radial pulse was palpated and confirmed that there was no 
pulse.  The local anaesthetic is then injected slowly over 90 seconds.  A 
standard volume of 40 ml of 0.5% lignocaine or 40 ml of 0.5% lignocaine 
with 0.5micrograms/kg dexmedetomidine was injected. Patients were 
divided into two groups according to the drug which they received .Group 
A patients received 40 ml of 0.5% lignocaine with 0.5micrograms/kg 
Dexmedetomidine and  Group B patients received 40 ml of 0.5% 
lignocaine and after achieving surgical anaesthesia, the distal tourniquet 
which overlies part of the anaesthetized arm was inflated and the proximal 
one was deflated.  After that the surgeons were allowed to proceed. 
 Intraoperatively, Pulse rate, Blood Pressure, Respiratory rate, SPO2, 
signs of drug toxicity were monitored regularly. If  patient complained of 
tourniquet pain (VAS >3), they were supplemented with Inj. Fentanyl 1 
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microgram/kg IV  and  intercostobrachial nerve block with local 
infiltration around the cuff.  The cuff was not deflated until 30 minutes 
after local anaesthetic injection even if surgery was completed before 30 
minutes and not inflated more than 90 minutes.  Cuff deflation was 
performed in cycles with deflation / inflation times of less than 10 seconds 
until the patient no longer exhibits signs of systemic toxicity.  Patients 
were observed for 30 minutes after surgery. 
Intraoperatively the following parameters were noted : 
1 Onset of action with sensory and motor blockade 
2. Pulse rate, Blood Pressure, Respiratory rate, SPO2 were monitored 
regularly at  5,10,15,20,30,40,50,60,75,90 and 120minutes 
3. Duration of surgery  
4. Sedation score 
5. Need of Rescue analgesia 
6. Side effects 
7. Duration of blockade after cuff deflation both sensory & motor 
Post operatively the time to first analgesic requirement was noted 
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RAMSAY SEDATION SCORE 
1- Patient  anxious and agitated or restless  
2- Patient  co-operative, oriented, and tranquil  
     3- Patient responds to commands only  
     4- Patient exhibits brisk response to light glabellar tap or loud auditory      
stimulus  
5- Patient exhibits a sluggish response to light  glabellar tap or loud 
auditory stimulus  
    6- Patient exhibits no response 
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DATA ANALYSIS 
 
In this study totally 60 patients were included. Patients were divided 
into two groups according to the drug which they received . Group A 
patients received 40 ml of lignocaine with 0.5microgram/kg 
Dexmedetomidine and Group B patients received 40 ml of 0.5% 
lignocaine. Data analysis was done with the help of computer using 
Epidemiological Information Package (EPI 2010) developed by Centre 
for Disease Control, Atlanta.  
 Using this software range, frequencies, percentages, means, standard 
deviations, chi square and  'p'  values were calculated. Kruskul Wallis chi-
square  test was used to test the significance of difference between 
quantitative variables and Yate’s chi square test for qualitative variables. A 
'p' value less than 0.05 is taken to denote significant relationship. 
 
 
 
 
 
 
Age distribution
9 9 7 5Group B
7 9 10 4
0% 10% 20% 30% 40% 50% 60% 70% 80% 90% 100%
Group A
20 - 29 yrs 30-39 yrs 40-49 yrs 50 & above
44 
 
OBSERVATION AND RESULTS 
 Age distribution 
Age group 
Group A Group B 
No % No % 
20 – 29 years 7 23.3 9 30 
30 – 39 years 9 30 9 30 
40 – 49 years 10 33.3 7 23.3 
50 & Above 4 13.3 5 16.7 
Total 30 100 30 100 
Range 23 – 53 years 20-56 years 
Mean 37.8 years 36.8 years 
SD 8.7 years 10.8 years 
‘p’ 
0.6148 
Not significant 
 
 Mean age of group A was 37.8 years and that of group B was 36.8 
years. There was no significant difference (p = 0.6148). 
Sex distribution 
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Sex distribution 
Age group 
Group A Group B 
No % No % 
Male 17 56.7 19 63.3 
Female 13 43.3 11 36.7 
Total 30 100 30 100 
‘p’ 
0.7921 
Not significant 
 
 56.7 % of Group A and 63.3% of Group B were males. The sex 
distribution did not have any statistically significant difference ( p > 
0.05). 
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                                                  Weight 
         
 
 
 
 
 
 Mean weights of the two groups of patients ( 52.5 kgs and 52.9 
kgs) were not significantly different ( p = 0.8471). 
 
 
 
 
                                                   
 
 
 
 
Parameter 
Weight (in kgs) 
Group A Group B 
Range 43 – 60 45 – 62 
Mean 52.5 52.9 
SD 5.0 5.5 
‘p’ 
0.8471 
Not significant 
TYPE OF SURGERY 
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                                     TYPE OF SURGERY  
 
Surgery done 
Group A Group B 
 
No 
 
% 
 
No 
 
% 
Ganglion excision 12 40 10 33.3 
K .Fix for # phalanx 11 36.7 9 30 
Tendon Repair 4 13.3 7 23.3 
SSG 3 10 4 13.3 
Total 30 100 30 100 
 
       Ganglion excision and k wire fixation for # phalanx were the most 
common surgeries performed in both the groups 
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Sensory onset time 
 
Parameters 
Sensory onset time ( in 
minutes) 
Group A Group B 
Range 1-3 4-6 
Mean 1.8 5.27 
SD 0.76 0.58 
‘p’ 
0.0001 
Significant 
 
 The sensory onset time of Group A was 1.8 + 0.76 minutes, This is 
significantly lower than the sensory onset time of Group B ( 5.27 + 0.58 
minutes) with a ‘p’ value of 0.0001 
MOTOR ONSET TIME  
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Motor onset time 
  
Parameters 
Motor onset time ( in 
minutes) 
Group A Group B 
Range 10-15 16-20 
Mean 13.63 18.07 
SD 1.54 1.26 
‘p’ 
0.0001 
Significant 
 
  The motor onset time of Group A (13.63 +1.54 minutes) was 
statistically significant ( p = 0.0001) from that of Group B ( 18.07 +1.26 
minutes). 
DURATION OF SURGERY  
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DURATION OF SURGERY 
 
Parameters 
Duration of surgery ( in 
minutes) 
Group A Group B 
Range 39-56 40-55 
Mean 46.83 47.43 
SD 5.07 4.79 
‘p’ 
0.6354 
Not significant 
 
 Duration of surgery was similar in both the groups with no 
statistically significant difference. 
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     RESCUE ANALGESIA 
 
Rescue Analgesia 
Group A Group B 
no % no % 
Yes - - 21 70 
No 30 100 9 30 
‘p’ 
0.0001 
Significant 
 
 21 cases in Group B required rescue analgesia whereas not even a 
single patient in Group A required it. This was statistically significant            
(p = 0.0001). 
SENSORY RECOVERY TIME  
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SENSORY RECOVERY TIME 
 
Parameters 
Sensory Recovery Time 
( in minutes) 
Group A Group B 
Range 10-22 3-6 
Mean 18.87 4.8 
SD 3.27 0.71 
‘p’ 
0.0001 
Significant 
 
 Sensory recovery time after the release of tourniquet was 18.87 + 
3.27 minutes in Group A and it was significantly lower at 4.8 + 0.71 
minutes in Group B. 
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MOTOR RECOVERY TIME 
 
Parameters 
Motor Recovery time 
( in minutes) 
Group A Group B 
Range 15 – 35 2-3 
Mean 25.6 2.53 
SD 3.83 0.51 
‘p’ 
0.0001 
Significant 
 
 Motor recovery time was significantly longer (25.6 + 3.83 minutes) 
for Group A than for Group B (2.53 + 0.51 minutes) which is statistically 
significant with a ‘p’ value of 0.0001 
 
 
 
 
 
 
  
 
 
                    
DURATION OF POSTOPERATIVE ANALGESIA 
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DURATION OF POSTOPERATIVE ANALGESIA (VAS > 3) 
 
Parameters 
Time when VAS > 3 ( in 
minutes) 
Group A Group B 
Range 280 – 490 10-13 
Mean 416.2 11.33 
SD 45.73 0.96 
‘p’ 
0.0001 
Significant 
 
 VAS reached a score of 3 at 416.2 + 45.73 minutes in Group A and 
at 11.33 + 0.96 minutes in Group B. This difference was statistically 
significant with a ‘p’ value of 0.0001. 
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MEAN ARTERIAL PRESSURE 
 
MAP at 
MAP Value (Mean+SD) 
for ‘p’ Significance 
Group A Group B 
1 minute 94.9 + 4.9 95.0 +5.7 0.8581 Not Significant
5 minutes 95.5 +3.3 94.8 +3.6 0.623 Not Significant
 
 Mean arterial pressures for both the groups were similar at 1 minute 
and at 5 minutes (p > 0.05) which is not statistically significant. 
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PULSE RATE 
 
Pulse rate at 
Pulse rate (Mean + SD) 
for ‘p’ Significance 
Group A Group B 
1 minute 82.7+ 5.8 81.6 +6 0.3926 Not Significant
5 minutes 82.0 +4.7 82.1 +4.9 0.9465 Not Significant
 
 Both at 1 minute and at 5 minutes, there was no statistically 
significant differences in the pulse rates between the two groups. 
SEDATION  SCORE 
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                                                      SEDATION SCORE 
 
Sedation score 
Group A Group B 
No % No % 
1 7 23.3 30 100 
2 23 76.7 - - 
Total 30 100 30 100 
Range 1-2 1 
Mean 1.77 1 
SD 0.43 - 
‘p’ 
0.0001 
Significant 
 
 In group A, 7 cases had a sedation score of 1 and 23 had a score of  
2. In group B, 30 cases  had sedation score of 1. 
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DISCUSSION 
   Intravenous regional anaesthesia uses local anaesthetics 
administered to one particular limb by occluding the arm proximally to 
provide conduction blockade.  It must be safe, not threatening or 
unpleasant to the patient, allow adequate surgical access to the operative 
site, and cause as little disturbance as possible to the internal homeostatic 
mechanisms. 
 Intravenous regional anaesthesia has many advantages. It is  simple, 
reliable with rapid onset and recovery.  Despite these advantages 
intravenous regional anaesthesia has its own limitations like lack of  
postoperative analgesia and tourniquet pain which causes discomfort to the 
patient. In this study, we attempted to eliminate these disadvantages by 
adding Dexmedetomidine as an adjuvant.   
Comparison of results: 
In this study both Group A(lignocaine with Dexmedetomidine) and 
Group B (lignocaine only) patients were comparable in respect of age, sex, 
weight and duration of surgery. 
 In my study, the onset of sensory and motor blockade was rapid  in 
Group A compared to Group B. Duration of blockade after cuff 
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deflation, both sensory and motor has similar recovery profile. This results 
correlate with studies conducted by Esmaoglu, A et al. 
 Incidence of tourniquet pain which was assessed by supplementation 
during surgery was significantly less in Group A (0%) than  Group B 
(70%) which was statistically significant and the p value is 0.0001. Similar 
study conducted by Memis et al shows incidence of tourniquet pain was 
less with when Dexmedetomidine as an additive. 
 The duration of post operative analgesia which was assessed by time 
to first analgesic requirement, in Group A is 416.2 + 45.73 minutes and in 
Group B is 19.4+/- 11 minutes. The p value is 0.0001, which is highly 
significant. The sedation score in Group A was 1.77±0.43 and in Group B 
was 1.00. The p value is 0.0001  
 The mechanism of tourniquet pain remains unclear despite the 
role of A fibers and unmyelinated C fibere.Dexmedetomidine  depress 
nerve action potentials, especially in C fibres, by a mechanism 
independent of the stimulation of α-2-adrenergic receptors . This 
mechanism accounts for strengthening of the local anesthetic block 
achieved by perineural administration of the drug and could be 
implicated in the effect seen in this study. Finally, α-2-adrenergic 
receptors located at nerve endings may have a role in the analgesic 
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effect of the drug by preventing norepinephrine release. In this 
study,it is found  that dexmedetomidine, in addition to its local 
anesthetic effect, delayed the onset of tourniquet pain and reduced 
intra- and postoperative analgesic requirement.  
Considering all the above said factors Dexmedetomidine in the dose 
of 0.5micrograms/kg can be used as a adjuvant for intravenous regional 
anaesthesia with improved duration of postoperative analgesia  
and decreased incidence of tourniquet pain.  
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SUMMARY 
This study was carried out at Govt. Rajaji hospital, Madurai, in 60 
patients of age 20-60 years, with ASA physical status I, who underwent 
forearm and hand  surgeries. They were divided into two groups of 30 
each.  
Group A : Intravenous regional anesthesia with 40ml of 0.5% lignocaine  
with dexmedetomidine 0.5micrograms/kg added as an adjuvant 
Group B : Intravenous regional anesthesia with 40ml of 0.5% lignocaine 
This study showed that   
1. Dexmedetomidine when added with lignocaine in Intravenous 
regional anesthesia provided longer duration of postoperative 
analgesia than with lignocaine alone. 
2. Sensory and motor onset time were decreased in Group A than 
Group B 
3. Patient comfortability in terms of sedation is better in Group A than 
Group B 
4. Less incidence of tourniquet pain in Group A than Group B 
5. Cardiovascular stability was similar in both the groups 
6. No side effects were noted in both the groups. 
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                                         CONCLUSION 
  From the data and the statistical analysis it is concluded that when 
Dexmedetomidine 0.5micrograms/kg is added to lignocaine for 
Intravenous regional anesthesia, it provided  quicker onset of sensory and 
motor blockade, lesser  incidence of tourniquet pain , increased  duration 
of post operative analgesia and  better haemodynamic stability without any 
side effects . 
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                                                  PROFORMA 
DEXMEDETOMIDINE AS AN ADJUVANT TO LIGNOCAINE IN  
INTRAVENOUS REGIONAL ANESTHESIA 
Name  :     Age / Sex : 
IP No.  :     Weight : 
Diagnosis :     ASA Risk : 
Surgery  : 
Premedication : 
 
Group A: Intravenous regional anesthesia with 40ml of 0.5% lignocaine  
with dexmedetomidine 0.5micrograms/kg added as an adjuvant 
Group B : Intravenous regional anesthesia with 40ml of 0.5% lignocaine 
 
1. Onset of action   Sensory : 
     Motor : 
2. Side effects noted  : 
3. Duration of surgery  : 
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Time Pre 5 10 15 20 30 40 60 75 90 120 
HR            
BP            
Sedation             
 
4. Supplementation : 
5. Duration blockade after cuff deflation        Sensory   : 
           Motor     : 
6. Post operative : 
  Time to first analgesic requirement 
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1 min 
 
5min 
 
1min 
 
5min 
1 Pandiyarajan 26 m 33208  52 Gang Excisi 1 12 40 no 10 20 480 96 99 76 80 2 
2 Sasikumar 33 m 32795 60 Gang  Excisi 1 10 43 no 20 30 300 92 97 86 83 2 
3 Jeyanthi  23 f 36500 50 Gang  Excisi 1 11 44 no 22 28 390 95 100 88 79 2 
4 Rameshwari  33 f 34201 53 #RF2 K Fix 3 12 45 no 12 20 280 90 96 84 87 2 
5 Periyakarupan  43 m 37045 55 #RF5 K Fix 3 10 39 no 15 25 475 98 101 80 89 2 
6 Suseela  32 f 35767 56 Gang  Excisi 1 12 41 no 10 15 490 102 94 90 84 2 
7 Vanaraj  40 m 40047 57 #RF3 K Fix 2 14 50 no 22 35 470 88 92 87 85 1 
8 Ranjitha  24 f 43015 47 Gang  Excisi 1 15 43 no 16 27 450 97 93 81 78 2 
9 Muthu  43 m 33870 56 Gang  Excisi 2 14 40 no 18 24 415 96 99 76 73 2 
10 Kumar  34 m 40869 60 Gang  Excisi 3 15 42 no 20 30 430 102 94 90 84 1 
11 Eswari  33 f 38667 54 Gang  Excisi 2 13 45 no 18 28 410 88 91 71 78 2 
12 Rajeshwari  29 f 32884 57 Gang  Excisi 3 15 41 no 20 24 416 88 92 87 85 2 
13 Selvam  40 m 35771 50 R FA SSG 1 15 49 no 22 30 430 97 93 81 78 1 
14 Pandi  52 m 38992 54 FTI Repair  2 12 50 no 20 25 450 102 94 90 84 2 
15 Ramu 39 m 36778 48 #RF3 K Fix 2 13 52 no 18 22 415 99 93 74 80 2
16 Vasanthi  37 f 37988 43 #LF4 K Fix 1 15 51 no 19 25 400 90 96 84 87 2 
17 Mari  42 m 35884 48 #RF2 K Fix 1 14 48 no 20 26 390 98 101 80 89 2 
18 Rajammal  45 f 35771 56 #lF5 K Fix 2 15 47 no 22 30 390 88 92 87 85 1 
19 Pandeeswari  52 f 38992 53 Gang  Excisi 1 14 43 no 21 25 450 97 93 81 78 2 
20 Murugan  49 m 37988 57 L FA SSG 3 15 45 no 20 22 420 96 99 76 73 2 
21 Kuppan  39 m 35991 45 FTI Repair  2 15 55 no 20 27 380 102 94 90 84 2 
22 Rakku  42 f 34779 55 FTI Repair  3 14 53 no 22 25 400 88 91 71 78 2 
23 Raju  45 m 36683 49 #RF3 K Fix 2 15 52 no 19 29 410 88 92 87 85 1 
24 Muthu  50 m 32772 43 #LF2 K Fix 2 13 55 no 20 24 460 97 93 81 78 2 
25 Meenakshi  27 f 33763 50 Gang  Excisi 1 15 42 no 22 23 425 96 99 76 73 1 
26 Kumar  29 m 33225 56 Gang  Excisi 2 14 45 no 19 26 385 102 94 90 84 2 
27 Ramaye  40 f 35569 45 R FA SSG 2 15 56 no 21 28 390 90 96 84 87 2 
28 Marimuthu  35 m 35583 57 #RF5 K Fix 1 14 49 no 19 27 410 98 101 80 89 2 
29 Pandi  53 m 32662 60 #LF3 K Fix 2 13 54 no 20 25 450 92 97 86 83 2 
30 Devi  26 f 32289 50 FTI Repair  1 15 46 no 19 23 425 95 100 88 79 1 
 
  
 
 
Group B 
1 Selvam  25 m 33802 52 Gang  Excisi 5 20 42 no 3 2 12 92 97 86 83 - 
2 Lakshmi  20 f 32476 45 Gang  Excisi 6 18 44 S 4 2 11 90 96 84 87 - 
3 Rajendran  35 m 36603 54 #RF3 K Fix 4 19 54 S 5 3 11 98 101 80 89 - 
4 Dinesh  25 m 34108 60 FTI Repair  5 20 47 s 4 2 10 102 94 90 84 - 
5 Eswari  27 f 37065 47 Gang  Excisi 5 19 41 no 5 2 11 88 91 71 78 - 
6 Devagi  30 F 40058 48 Gang Excisi 6 17 42 no 4 3 12 103 97 80 84 - 
7 kaliammal 32 f 38651 45 Gang  Excisi 5 19 42 no 5 2 11 100 95 75 79 - 
8 Karthik  29 m 43209 57 Gang  Excisi 6 20 40 no 4 3 10 102 94 90 84  
9 Nagalaksmi  40 f 36470 52 L FA SSG 5 18 47 s 4 2 12 88 92 87 85 - 
10 Anandavalli  34 f 38992 47 FTI Repair  6 16 52 s 5 3 10 97 93 81 78 - 
11 Nagarajan  46 m 32287 55 FTI Repair  5 20 53 s 5 2 13 96 99 76 73 - 
12 Velliammal  56 f 40138 45 #RF2 K Fix 6 18 49 s 4 2 11 90 96 84 87 - 
13 Irulandi  50 m 33879 56 #LF3 K Fix 5 17 46 s 5 3 12 91 94 79 82 - 
14 Saravanan  35 m 40208 60 #RF2 K Fix 6 19 50 s 5 3 11 101 96 83 89 - 
15 Kuppan  56 m 38665 48 R FA SSG 5 18 49 s 6 3 10 88 92 87 85 - 
16 Pandiselvi  40 f 34456 45 L FA SSG 4 19 43 no 5 3 12 97 93 81 78 - 
17 Vellusamy  52 m 42335 57 Gang  Excisi 5 18 42 no 5 3 11 96 99 76 73 - 
18 Rajendran  49 m 39237 53 Gang Excisi 6 17 45 s 5 3 10 102 94 90 84 -
19 Mani  35 m 40336 58 Gang  Excisi 6 18 41 no 5 2 11 88 91 71 78 - 
20 Satheesh  32 m 32265 62 FTI Repair  5 16 46 s 6 3 13 88 92 87 85 - 
21 Selvi  23 f 38896 47 FTI Repair  5 19 54 s 5 3 12 97 93 81 78 - 
22 Vellian  48 m 39335 59 #RF2 K Fix 6 17 47 s 5 2 11 96 99 76 73 - 
23 Raju  25 m 37552 52 L FA SSG 5 16 55 s 6 3 13 90 96 84 87 - 
24 Krishnan  45 m 43116 59 #RF3 K Fix 5 19 53 s 5 2 11 98 101 80 89 - 
25 Sathyan  22 m 37795 60 #LF4 K Fix 5 17 48 s 6 3 10 89 84 86 83 -
26 Muthalgu  26 f 33315 49 #RF2 K Fix 5 18 54 s 5 3 12 104 99 70 76 - 
27 Vijayan  42 m 47765 48 #LF5 K Fix 5 19 51 s 5 2 11 87 90 73 80 - 
28 Ramu  38 m 39226 60 Gang  Excisi 5 16 42 no 4 2 13 102 94 90 84 - 
29 Maniammal  35 f 44553 52 FTI Repair  6 18 53 s 5 2 11 101 96 85 79 - 
30 Subramani  53 m 39965 55 FTI Repair  5 17 51 s 4 3 12 90 96 84 87 - 
